Thomas Sciascia insider trades: Trevi Therapeutics (TRVI) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Thomas reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | TRVI | ↓ Sell | 2,631 | $6.60 | $17K | Direct | Mar 26, 2025 (1d) |
| Aug 19, 2024 | TRVI | ↓ Sell | 16,496 | $2.96 | $49K | Direct | Aug 21, 2024 (2d) |
| Aug 16, 2024 | TRVI | ↓ Sell | 31,505 | $2.77 | $87K | Direct | Aug 16, 2024 (0d) |
| May 29, 2024 | TRVI | ↓ Sell | 53,368 | $2.55 | $136K | Direct | May 31, 2024 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TRVI insiders
Open-market trades in the last 12 months
About Thomas Sciascia's insider trades
Thomas Sciascia is Chief Scientific Officer at Trevi Therapeutics (TRVI). Since May 29, 2024, Thomas has reported no open-market purchases and 4 sales worth $290K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (18 filings), option exercises (4 filings), conversions (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TRVI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.